Abstract
Neurofibromatosis type 2 (NF2) with onset before the first year of life has been anecdotally reported in the literature. We (a) prospectively (years 1997–2012) followed up three unrelated NF2 children, all harbouring NF2 gene mutations whose onset of disease was before age 1 year, and (b) systematically reviewed published reports on NF2 in the youngest age group (i.e. onset <1 year). The present three children had (1) small (<1 cm), bilateral vestibular schwannomas (VSs) detected (as an incidental finding) at magnetic resonance imaging (MRI) by the age of 4 to 5 months that were asymptomatic for 10 to 14 years, with sudden and rapid (<12 months) progression in two cases at the age of 11 and 15 years, respectively; (2) development of large numbers of skin NF2 plaques mainly in atypical locations (i.e. face, hands, legs and knees), which reverted to normal skin appearance at the time of VSs progression; (3) lens opacities (n = 1) and NF2 retinal changes (n = 2) detected as early as age of 3-4 months; (4) diffuse (asymptomatic) high signal lesions at brain MRI in the periventricular regions (alike cortical dysplasia); and (5) unaffected first-degree relatives who did not harbour NF2 gene abnormalities. This represents the youngest NF2 group with the longest prospective follow-up so far reported. NF2 may present as a congenital form with bilateral VSs presenting as early as the first months of life and with natural history different to that which occurs in classical NF2.
Similar content being viewed by others
References
Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, Evans DG (2011) Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 13:576–81
Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21–34
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618
Mautner VE, Tatagiba M, Guthoff R, Samili M, Pulst SM (1993) Neurofibromatosis type 2 in the pediatric age. Neurosurgery 33:92–96
MacCollin M, Mautner VE (1998) The diagnosis and management of neurofibromatosis type 2 in childhood. Semin Pediatr Neurol 5:243–252
Evans DG, Birch JM, Ramsden RT (1999) Pediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496–499
Ruggieri M, Huson SM (1999) Clinical presentations of neurofibromatosis type 2 in childhood. Eur J Pediatr Neurol 3:66
Nunes F, MacCollin M (2002) Neurofibromatosis type 2 in the pediatric population. J Child Neurol 18:718–724
Rushing EJ, Olsen C, Mena H, Rueda ME, Lee YS, Keating RF, Packer RJ, Santi M (2005) Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 103(Suppl):489–495
Bosch MM, Boltshauser E, Harpes P, Landau K (2006) Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 141:1068–1077
Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J (2009) Neurofibromatosis type 2 (NF2). Study of 7 patients. Neurologia 24:457–461
Ruggieri M, Huson S (2001) The clinical and diagnostic implications of mosaicism in the neurofibromatosis. Neurology 56:1433–1443
Huson SM, Hughes RAC (1994) The neurofibromatoses. A pathogenic and clinical overview. Churchill Livingstone, London
Ruggieri M, Pacual-Castroviejo I, Di Rocco C (2008) Neurocutaneous disorders. Phakomatoses and hamartoneoplastic syndromes. Springer, New York
Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M (2012) Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 34:459–468
Ruggieri M, Iannetti P, Clementi M, Polizzi A, Incorpora G, Spalice A, Pavone P, Praticò AD, Elia M, Gabriele AL, Tenconi R, Pavone L (2009)Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst 25:211–6
Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367
Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18
Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–5
Acknowledgments
The authors wish to thank Mr. Marco Di Mauro (University of Catania) and Mr. Francesco Marino (CNR, Catania) for their skilful technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruggieri, M., Gabriele, A.L., Polizzi, A. et al. Natural history of neurofibromatosis type 2 with onset before the age of 1 year. Neurogenetics 14, 89–98 (2013). https://doi.org/10.1007/s10048-013-0354-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-013-0354-0